Medical Science
| Open Access |
DOI: Modern Approaches To Comprehensive Treatment Of Erythematous-Bullous Erysipelas In Patients: Achievements And Shortcomings (Literature Review)
Ergashev Ulugbek Yusufjanovich , DSc, professor, Head of Department of General Surgery No.2, Tashkent State Medical University, Tashkent, Uzbekistan Zokhirov Adkhamjon Rafiqovich , PhD, Senior teacher of Department of General Surgery No.2, Tashkent State Medical University, Tashkent, Uzbekistan Istamov Maxmudali Iskandar ogli , Assistant of Department of General Surgery No.2, Tashkent State Medical University, Tashkent, UzbekistanAbstract
As a result of clinical and epidemiological observations by many authors over the past decade, changes in the clinical course of sarcasm have been noted. In particular, a significant increase in the number of purulent-necrotic forms has been revealed, the number of disease relapses has not decreased, their frequent development and high mortality remain. Analysis of available scientific data shows that currently, there is no clearly developed program for the use of magnetic laser therapy in the complex treatment of complicated forms of sarcasm. Information on the morphological features of ulcerative processes and changes in local microcirculation under the influence of this therapy is also insufficient. The significance of the aforementioned problem in practical medicine and the presence of many unexplored issues served as the basis for conducting this scientific research.
Keywords
Measles inflammation, intravenous laser blood irradiation, photodynamic therapy
References
AMBOSS GmbH . AMBOSS. AMBOSS GmbH; Berlin, Germany: 2024. Lymphedema.
AMBOSS GmbH . AMBOSS. AMBOSS GmbH; Berlin, Germany: 2025. Skin and Soft Tissue Infections.
Blackburn J., Kopecki Z., Ousey K.J. Skin integrity, antimicrobial stewardship and infection control: A critical review of current best practice. Wound Pract. Res. 2024;32:34–43. doi: 10.33235/wpr.32.1.34-43.
Boucher H. Sanford Guide to Antimicrobial Therapy [Mobile App] Antimicrobial Therapy, Inc.; Sperryville, VA, USA: 2025. Erysipelas, Recurrent, Lymphedema.
Bowen A.C., Carapetis J.R., Currie B.J., Fowler V., Jr., Chambers H.F., Tong S.Y.C. Sulfamethoxazole-Trimethoprim (Cotrimoxazole) for Skin and Soft Tissue Infections Including Impetigo, Cellulitis, and Abscess. Open Forum Infect. Dis. 2017;4:ofx232. doi: 10.1093/ofid/ofx232.
Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal disease. Lancet Infect Dis. 2015;5:685-94.
Cross E.L.A., Quan T.P., Hayward G.N., Walker A.S., Llewelyn M.J. Development and validation of the Baseline Recurrence Risk in Cellulitis (BRRISC) score. J. Infect. 2024;88:103–111. doi: 10.1016/j.jinf.2023.12.007.
Dalal A., Eskin-Schwartz M., Mimouni D., Ray S., Days W., Hodak E., Leibovici L., Paul M. Interventions for the prevention of recurrent erysipelas and cellulitis. Cochrane Database Syst. Rev. 2017;6:CD009758. doi: 10.1002/14651858.CD009758.pub2
Executive Committee of the International Society of Lymphology The diagnosis and treatment of peripheral lymphedema:2020 Consensus Document of the International Society of Lymphology. Lymphology. 2020;53:3–19. doi: 10.2458/lymph.4649.
Greene A.K., Grant F.D., Slavin S.A., Maclellan R.A. Obesity-induced lymphedema: Clinical and lymphoscintigraphic features. Plast. Reconstr. Surg. 2015;135:1715–1719. doi: 10.1097/PRS.0000000000001271.
Inghammar M., Rasmussen M., Linder A. Recurrent erysipelas-risk factors and clinical presentation. BMC Infect. Dis. 2014;14:270. doi: 10.1186/1471-2334-14-270.
Krakauer T., Buckley M. Doxycycline is anti-Inflammatory and inhibits staphylococcal exotoxin-induced cytokines and chemokines. Antimicrob. Agents Chemother. 2003;47:3630–3633. doi: 10.1128/AAC.47.11.3630-3633.2003.
Kremer M., Zuckerman R., Avraham Z., Raz R. Long-term antimicrobial therapy in the prevention of recurrent soft-tissue infections. J. Infect. 1991;22:37–40. doi: 10.1016/0163-4453(91)90898-3.
Leszczyszyn-Pynka M. Interna Szczeklika 2025. 19th ed. Medycyna Praktyczna; Kraków, Poland: 2025. Erysipelas; pp. 2490–2491.
Li A., Wang N., Ge L., Xin H., Li W. Risk factors of recurrent erysipelas in adult Chinese patients: A prospective cohort study. BMC Infect. Dis. 2021;21:26. doi: 10.1186/s12879-020-05710-3.
Macy E. Addressing the epidemic of antibiotic “allergy” over-diagnosis. Ann. Allergy Asthma Immunol. 2020;124:550–557. doi: 10.1016/j.anai.2019.12.016.
Macy E. Penicillin allergy: Optimizing diagnostic protocols, public health implications, and future research needs. Curr. Opin. Allergy Clin. Immunol. 2015;15:308–313. doi: 10.1097/ACI.0000000000000173.
Matych M., Ciosek A., Miler K., Noweta M., Brzezińska K., Sarzała M., Narbutt J., Lesiak A. Primary and Recurrent Erysipelas-Epidemiological Patterns in a Single-Centre Retrospective Analysis. J. Clin. Med. 2025;14:5299. doi: 10.3390/jcm14155299.
Michael Y., Shaukat N.M. StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2025. [(accessed on 30 August 2025)].
National Institute for Health and Care Excellence (NICE) Cellulitis and Erysipelas: Antimicrobial Prescribing. NICE Guideline NG141, UK, 27 September 2019.
Nguyen L., Rowland K. Low-dose penicillin for recurrent cellulitis? J. Fam. Pract. 2014;63:E10–E12.
Olszewski W.L., Zaleska M.T. Long-Term Benzathine Penicillin Prophylaxis Lasting for Years Effectively Prevents Recurrence of Dermato-Lymphangio-Adenitis (Cellulitis) in Limb Lymphedema. Lymphat. Res. Biol. 2021;19:545–552. doi: 10.1089/lrb.2020.0051.
Ong B.S., Dotel R., Ngian V.J.J. Recurrent Cellulitis: Who is at Risk and How Effective is Antibiotic Prophylaxis? Int. J. Gen. Med. 2022;15:6561–6572. doi: 10.2147/IJGM.S326459.
Ortiz-Lazo E., Arriagada-Egnen C., Poehls C., Concha-Rogazy M. An Update on the Treatment and Management of Cellulitis. Actas Dermo-Sifiliogr. 2019;110:124–130. doi: 10.1016/j.adengl.2019.01.011.
Piekarska A., Panasiuk A., Stępień P.M. Clinical practice guidelines for Clostridioides (Clostridium) difficile infection and fecal microbiota transplant protocol—Recommendations of the Polish Society of Epidemiology and Infectious Diseases. Przegl. Epidemiol. 2020;74:69–87. doi: 10.32394/pe.74.06.
Sapuła M., Krankowska D., Wiercińska-Drapało A. In Search of Risk Factors for Recurrent Erysipelas and Cellulitis of the Lower Limb: A Cross-Sectional Study of Epidemiological Characteristics of Patients Hospitalized due to Skin and Soft-Tissue Infections. Interdiscip. Perspect. Infect. Dis. 2020;2020:1307232. doi: 10.1155/2020/1307232.
Stevens D.L., Bisno A.L., Chambers H.F., Dellinger E.P., Goldstein E.J.C., Gorbach S.L., Hirschmann J.V., Kaplan S.L., Montoya J.G., Wade J.C., et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2014;59:e10–e52. doi: 10.1093/cid/ciu296.
Taylor E., Nailor M.D., Feider M., Sullivan S., Goodlet K.J. Doxycycline versus cephalexin treatment of presumed streptococcal skin and soft tissue infection among adults presenting to the emergency department. Antimicrob. Agents Chemother. 2024;68:e01282-23. doi: 10.1128/aac.01282-23.
Thomas K.S., Crook A.M., Nunn A.J., Foster K.A., Mason J.M., Chalmers J.R., Nasr I.S., Brindle R.J., English J., Meredith S.K., et al. Penicillin to Prevent Recurrent Leg Cellulitis. N. Engl. J. Med. 2013;368:1695–1703. doi: 10.1056/NEJMoa1206300.
Toschi A., Giannella M., Viale P. Recurrence of skin and soft tissue infections: Identifying risk factors and treatment strategies. Curr. Opin. Infect. Dis. 2025;38:71–77. doi: 10.1097/QCO.0000000000001096.
UK Dermatology Clinical Trials Network’s PATCH Trial Team. Thomas K., Crook A., Foster K., Mason J., Chalmers J., Bourke J., Ferguson A., Level N., Nunn A., et al. Prophylactic antibiotics for the prevention of cellulitis (erysipelas) of the leg: Results of the UK Dermatology Clinical Trials Network’s PATCH II trial. Br. J. Dermatol. 2012;166:169–178. doi: 10.1111/j.1365-2133.2011.10586.x.
Webb E., Neeman T., Bowden F.J., Gaida J., Mumford V., Bissett B. Compression Therapy to Prevent Recurrent Cellulitis of the Leg. N. Engl. J. Med. 2020;383:630–639. doi: 10.1056/NEJMoa1917197.
Брико НИ, Филатов НН, Еровиченков АА, Журавлев МВ, Бражников АЮ. Клинико-эпидемиологическая характеристика стрептококковой (группы А) инфекции на современном этапе. Терапевтический архив. 2022; 11:26-31.
Брико Н.И. Стратегия и тактика эпидемиологического надзора за стрептококковой инфекцией. Микробиология. 2019; 2:103-7.
Глухов А.А., Бражник Е.А. Современный подход к комплексному лечению рожистого воспаления. Фундаментальные исследования. – 2024. – № 10 (часть 2) – С. 411-415
Еровиченков А.А., Черкасов В.Л. Рожа: клиника, диагностика, лечение. Российский медицинский журнал. №8. 2021.
Лучшев, В. И., Жаров, С. Н., Кузнецова, И. В. (2022). Рожа: клиника, диагностика, лечение. Российский медицинский журнал, (3), 42-44.
Плавунов Н.Ф., Кадышев В.А., Чернобровкина Т.Я., Проскурина Л.Н. Особенности клиники и дифференциальной диагностики рожи. обзор. Архив внутренней медицины. 2020; 7(5): 327-339.
Рожа: вопросы и ответы. «Инфекционная клиническая больница №2 Департамента здравоохранения города Москвы». (2023). ВОЗ призывает к глобальным действиям по борьбе с сепсисом, вызывающим каждую пятую смерть в мире. ВОЗ.
Фазылов, В. Х., Гилмуллина, Ф. С., Загидуллина, А. И. (2024). Рожа: клинико-диагностические и лечебно-профилактические аспекты. Практическая медицина, (4 (9)), 3-7.
Article Statistics
Downloads
Copyright License
Copyright (c) 2025 Ergashev Ulugbek Yusufjanovich, Zokhirov Adkhamjon Rafiqovich, Istamov Maxmudali Iskandar ogli
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.